Skip to main content
SpringerLink
Log in

HLA and lung transplantation

  • Review
  • Published:
Frontiers of Medicine Aims and scope Submit manuscript

Abstract

Lung transplantation is increasingly practiced for patients with end-stage lung disease. The successful outcome of solid organ transplantation today is severely impeded by the production of alloantibodies, mainly directed against the protein products of the HLA complex of the organ donor. While the association between antibody mediated rejection and allograft damage has been well established in renal and heart transplantation, it has not yet been well characterized in lung transplantation. This review addresses the question of HLA matching in lung transplantation and current knowledge of the allogenicity of different HLA class I and II antigens. The role of the antibody mediated immune response is discussed as well as the importance of pre-transplant or de novo post-transplant circulating antibodies. Finally, potential mechanisms, which may act individually or in combination, of antibody mediated damage to solid organ transplants are considered.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Similar content being viewed by others

References

  1. Yusen RD, Edwards LB, Kucheryavaya AY, Benden C, Dipchand AI, Dobbels F, Goldfarb SB, Levvey BJ, Lund LH, Meiser B, Stehlik J; International Society for Heart and Lung Transplantation. The registry of the International Society for Heart and Lung Transplantation: thirty-first adult lung and heart-lung transplant report—2014; focus theme: retransplantation. J Heart Lung Transplant 2014; 33(10): 1009–1024

    Article  PubMed  Google Scholar 

  2. Organ Procurement and Transplantation Network (OPTN) and Scientific Registry of Transplant Recipients(SRTR). OPTN/SRTR 2010 Annual Data Report. Rockville, MD: Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation, 2011

  3. Levine DJ, Glanville AR, Aboyoun C, Belperio J, Benden C, Berry GJ, Hachem R, Hayes D Jr, Neil D, Reinsmoen NL, Snyder LD, Sweet S, Tyan D, Verleden G, Westall G, Yusen RD, Zamora M, Zeevi A. Antibody-mediated rejection of the lung: a consensus report of the International Society for Heart and Lung Transplantation. J Heart Lung Transplant 2016; 35(4): 397–406

    Article  PubMed  Google Scholar 

  4. McManigle W, Pavlisko EN, Martinu T. Acute cellular and antibody-mediated allograft rejection. Semin Respir Crit Care Med 2013; 34(3): 320–335

    Article  PubMed  Google Scholar 

  5. Auffray C, Charron D, Hood L. Predictive, preventive, personalized and participatory medicine: back to the future. Genome Med 2010; 2(8): 57

    Article  PubMed  PubMed Central  Google Scholar 

  6. Robinson J, Halliwell JA, Hayhurst JH, Flicek P, Parham P, Marsh SGE. The IPD and IMGT/HLA database: allele variant databases. Nucleic Acids Res 2015;43(Database issue):D423–431

    Article  CAS  PubMed  Google Scholar 

  7. Wisser W, Wekerle T, Zlabinger G, Senbaclavaci O, Zuckermann A, Klepetko W, Wolner E. Influence of human leukocyte antigen matching on long-term outcome after lung transplantation. J Heart Lung Transplant 1996; 15(12): 1209–1216

    CAS  PubMed  Google Scholar 

  8. Smits JMA, Mertens BJA, Van Houwelingen HC, Haverich A, Persijn GG, Laufer G. Predictors of lung transplant survival in eurotransplant. Am J Transplant 2003; 3(11): 1400–1406

    Article  CAS  PubMed  Google Scholar 

  9. Quantz MA, Bennett LE, Meyer DM, Novick RJ. Does human leukocyte antigen matching influence the outcome of lung transplantation? An analysis of 3,549 lung transplantations. J Heart Lung Transplant 2000; 19(5): 473–479

    Article  CAS  PubMed  Google Scholar 

  10. Wong JY, Tait B, Levvey B, Griffiths A, Esmore DS, Snell GI, Williams TJ, Kotsimbos TC. Epstein-Barr virus primary mismatching and HLA matching: key risk factors for post lung transplant lymphoproliferative disease. Transplantation 2004; 78(2): 205–210

    Article  PubMed  Google Scholar 

  11. Bakker NA, van Imhoff GW, Verschuuren EA, van Son WJ, van der Heide JJ, Lems SP, Veeger NJ, Kluin PM, Kluin-Nelemans HC, Hepkema BG. HLA antigens and post renal transplant lymphoproliferative disease: HLA-B matching is critical. Transplantation 2005; 80(5):595–599

    Article  CAS  PubMed  Google Scholar 

  12. Opelz G, Süsal C, Ruhenstroth A, Döhler B. Impact of HLA compatibility on lung transplant survival and evidence for an HLA restriction phenomenon: a collaborative transplant study report. Transplantation 2010; 90(8): 912–917

    Article  CAS  PubMed  Google Scholar 

  13. Hayes D Jr, Whitson BA, Ghadiali SN, Tobias JD, Mansour HM, Black SM. Influence of HLA mismatching on survival in lung transplantation. Lung 2015; 193(5): 789–797

    Article  PubMed  Google Scholar 

  14. Hayes D Jr, Black SM, Tobias JD, Kopp BT, Kirkby SE, Mansour HM, Whitson BA. Influence of human leukocyte antigen mismatching on bronchiolitis obliterans syndrome in lung transplantation. J Heart Lung Transplant 2016; 35(2):186–194

    Article  PubMed  Google Scholar 

  15. Harjula AL, Baldwin JC, Glanville AR, Tazelaar H, Oyer PE, Stinson EB, Shumway NE. Human leukocyte antigen compatibility in heart-lung transplantation. J Heart Transplant 1987; 6(3): 162–166

    CAS  PubMed  Google Scholar 

  16. Sundaresan S, Mohanakumar T, Smith MA, Trulock EP, Lynch J, Phelan D, Cooper JD, Patterson GA. HLA-A locus mismatches and development of antibodies to HLA after lung transplantation correlate with the development of bronchiolitis obliterans syndrome. Transplantation 1998; 65(5): 648–653

    Article  CAS  PubMed  Google Scholar 

  17. Brugière O, Thabut G, Suberbielle C, Reynaud-Gaubert M, Thomas P, Pison C, Saint Raymond C, Mornex JF, Bertocchi M, Dromer C, Velly JF, Stern M, Philippe B, Dauriat G, Biondi G, Castier Y, Fournier M. Relative impact of human leukocyte antigen mismatching and graft ischemic time after lung transplantation. J Heart Lung Transplant 2008; 27(6): 628–634

    Article  PubMed  Google Scholar 

  18. Peltz M, Bennett Edwards L, Jessen ME, Torres F, Meyer DM. Impact of HLA class I and class II mismatching on lung transplant recipient mortality, rejection, and bronchiolitis obliterans. J Heart Lung Transplant 2006; 25(suppl): S112

    Article  Google Scholar 

  19. Chalermskulrat W, Neuringer IP, Schmitz JL, Catellier DJ, Gurka MJ, Randell SH, Aris RM. Human leukocyte antigen mismatches predispose to the severity of bronchiolitis obliterans syndrome after lung transplantation. Chest 2003; 123(6): 1825–1831

    Article  PubMed  Google Scholar 

  20. Schulman LL, Weinberg AD, McGregor C, Galantowicz ME, Suciu-Foca NM, Itescu S. Mismatches at the HLA-DR and HLA-B loci are risk factors for acute rejection after lung transplantation. Am J Respir Crit Care Med 1998; 157(6 Pt 1): 1833–1837

    Article  CAS  PubMed  Google Scholar 

  21. Iwaki Y, Yoshida Y, Griffith B. The HLA matching effect in lung transplantation. Transplantation 1993; 56(6): 1528–1564

    Article  CAS  PubMed  Google Scholar 

  22. Love RB, Meyer KC, Devito-Haynes LD, Ulschmid S, Leverson GE, Van Der Bij W, De Boer WJ, Hepkema BG, Cornwell RD, Woolley DS, Burlingham WJ. Effect of HLA-DR mismatch on lung transplant outcome. J Heart Lung Transplant 2001; 20(2): 177

    Article  PubMed  Google Scholar 

  23. Wan L, Chen DF. The influence of HLA antigen mismatch and epitope mismathe on lung transplant survival: analysis of OPTN data after LAS allocation. Hum Immunol 2015; 76: 124–167

    Article  Google Scholar 

  24. Butts RJ, Savage AJ, Nietert PJ, Kavarana M, Moussa O, Burnette AL, Atz AM. Effect of human leukocyte antigen-C and -DQ matching on pediatric heart transplant graft survival. J Heart Lung Transplant 2014; 33(12): 1282–1287

    Article  PubMed  PubMed Central  Google Scholar 

  25. Afzali B, Lombardi G, Lechler RI. Pathways of major histocompatibility complex allorecognition. Curr Opin Organ Transplant 2008; 13(4): 438–444

    Article  PubMed  Google Scholar 

  26. Herrera OB, Golshayan D, Tibbott R, Salcido Ochoa F, James MJ, Marelli-Berg FM, Lechler RI. A novel pathway of alloantigen presentation by dendritic cells. J Immunol 2004; 173(8): 4828–4837

    Article  CAS  PubMed  Google Scholar 

  27. Shilling RA, Wilkes DS. Immunobiology of chronic lung allograft dysfunction: new insights from the bench and beyond. Am J Transplant 2009; 9(8): 1714–1718

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Hachem RR. Lung allograft rejection: diagnosis and management. Curr Opin Organ Transplant 2009;14(5):477–482

    Article  PubMed  Google Scholar 

  29. Pober JS, Jane-wit D, Qin L, Tellides G. Interacting mechanisms in the pathogenesis of cardiac allograft vasculopathy. Arterioscler Thromb Vasc Biol 2014; 34(8): 1609–1614

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. DeNicola MM, Weigt SS, Belperio JA, Reed EF, Ross DJ, Wallace WD. Pathologic findings in lung allografts with anti-HLA antibodies. J Heart Lung Transplant 2013; 32(3): 326–332

    Article  PubMed  Google Scholar 

  31. Visentin J, Chartier A, Massara L, Linares G, Guidicelli G, Blanchard E, Parrens M, Begueret H, Dromer C, Taupin JL. Lung intragraft donor-specific antibodies as a risk factor for graft loss. J Heart Lung Transplant 2016; 35(12): 1418–1426

    Article  PubMed  Google Scholar 

  32. Hachem R. Antibody-mediated lung transplant rejection. Curr Respir Care Rep 2012; 1(3): 157–161

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  33. 2004 Annual Report of the U.S. Organ Procurement and Transplantation Network and the Scientific Registry of Transplant Recipients: Transplant Data 1994–2003. Department of Health and Human Services, Health Resources and Services Administration, Healthcare Systems Bureau, Division of Transplantation, Rockville, MD; United Network for Organ Sharing, Richmond, VA; University Renal Research and Education Association, Ann Arbor, MI

  34. Lau CL, Palmer SM, Posther KE, Howell DN, Reinsmoen NL, Massey HT, Tapson VF, Jaggers JJ, D’Amico TA, Davis RD Jr. Influence of panel-reactive antibodies on posttransplant outcomes in lung transplant recipients. Ann Thorac Surg 2000; 69(5): 1520–1524

    Article  CAS  PubMed  Google Scholar 

  35. Shah AS, Nwakanma L, Simpkins C, Williams J, Chang DC, Conte JV. Pretransplant panel reactive antibodies in human lung transplantation: an analysis of over 10,000 patients. Ann Thorac Surg 2008; 85(6): 1919–1924

    Article  PubMed  Google Scholar 

  36. Mangi AA, Mason DP, Nowicki ER, Batizy LH, Murthy SC, Pidwell DJ, Avery RK, McCurry KR, Pettersson GB, Blackstone EH. Predictors of acute rejection after lung transplantation. Ann Thorac Surg 2011; 91(6): 1754–1762

    Article  PubMed  Google Scholar 

  37. Hirche TO, Knoop C, Hebestreit H. Practical guidelines: lung transplantation in patients with cystic fibrosis. Pulm Med 2014; 2014:621342

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  38. Choi JK, Kearns J, Palevsky HI, Montone KT, Kaiser LR, Zmijewski CM, Tomaszewski JE. Hyperacute rejection of a pulmonary allograft. Immediate clinical and pathologic findings. Am J Respir Crit Care Med 1999; 160(3): 1015–1018

    Article  CAS  PubMed  Google Scholar 

  39. Frost AE, Jammal CT, Cagle PT. Hyperacute rejection following lung transplantation. Chest 1996; 110(2): 559–562

    Article  CAS  PubMed  Google Scholar 

  40. Bittner HB, Dunitz J, Hertz M, Bolman MR 3rd, Park SJ. Hyperacute rejection in single lung transplantation—case report of successful management by means of plasmapheresis and antithymocyte globulin treatment. Transplantation 2001; 71(5): 649–651

    Article  CAS  PubMed  Google Scholar 

  41. Masson E, Stern M, Chabod J, Thévenin C, Gonin F, Rebibou JM, Tiberghien P. Hyperacute rejection after lung transplantation caused by undetected low-titer anti-HLA antibodies. J Heart Lung Transplant 2007; 26(6): 642–645

    Article  PubMed  Google Scholar 

  42. Loupy A, Lefaucheur C, Vernerey D, Prugger C, Duong van Huyen JP, Mooney N, Suberbielle C, Frémeaux-Bacchi V, Méjean A, Desgrandchamps F, Anglicheau D, Nochy D, Charron D, Empana JP, Delahousse M, Legendre C, Glotz D, Hill GS, Zeevi A, Jouven X. Complement-binding anti-HLA antibodies and kidney-allograft survival. N Engl J Med 2013; 369(13): 1215–1226

    Article  CAS  PubMed  Google Scholar 

  43. Sicard A, Ducreux S, Rabeyrin M, Couzi L, McGregor B, Badet L, Scoazec JY, Bachelet T, Lepreux S, Visentin J, Merville P, Fremeaux-Bacchi V, Morelon E, Taupin JL, Dubois V, Thaunat O. Detection of C3d-binding donor-specific anti-HLA antibodies at diagnosis of humoral rejection predicts renal graft loss. J Am Soc Nephrol 2015; 26(2): 457–467

    Article  CAS  PubMed  Google Scholar 

  44. Tambur AR, Claas FH. HLA epitopes as viewed by antibodies: what is it all about? Am J Transplant 2015; 15(5): 1148–1154

    Article  CAS  PubMed  Google Scholar 

  45. Zhang Q, Cecka JM, Gjertson DW, Ge P, Rose ML, Patel JK, Ardehali A, Kobashigawa JA, Fishbein MC, Reed EF. HLA and MICA: targets of antibody-mediated rejection in heart transplantation. Transplantation 2011; 91(10): 1153–1158

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. Hachem RR, Yusen RD, Meyers BF, Aloush AA, Mohanakumar T, Patterson GA, Trulock EP. Anti-human leukocyte antigen antibodies and preemptive antibody-directed therapy after lung transplantation. J Heart Lung Transplant 2010; 29(9): 973–980

    Article  PubMed  PubMed Central  Google Scholar 

  47. Lobo LJ, Aris RM, Schmitz J, Neuringer IP. Donor-specific antibodies are associated with antibody-mediated rejection, acute cellular rejection, bronchiolitis obliterans syndrome, and cystic fibrosis after lung transplantation. J Heart Lung Transplant 2013; 32(1): 70–77

    Article  PubMed  Google Scholar 

  48. Snyder LD, Wang Z, Chen DF, Reinsmoen NL, Finlen-Copeland CA, Davis WA, Zaas DW, Palmer SM. Implications for human leukocyte antigen antibodies after lung transplantation: a 10-year experience in 441 patients. Chest 2013; 144(1): 226–233

    Article  PubMed  PubMed Central  Google Scholar 

  49. Girnita AL, McCurry KR, Iacono AT, Duquesnoy R, Corcoran TE, Awad M, Spichty KJ, Yousem SA, Burckart G, Dauber JH, Griffith BP, Zeevi A. HLA-specific antibodies are associated with highgrade and persistent-recurrent lung allograft acute rejection. J Heart Lung Transplant 2004; 23(10): 1135–1141

    Article  PubMed  Google Scholar 

  50. Palmer SM, Davis RD, Hadjiliadis D, Hertz MI, Howell DN, Ward FE, Savik K, Reinsmoen NL. Development of an antibody specific to major histocompatibility antigens detectable by flow cytometry after lung transplant is associated with bronchiolitis obliterans syndrome. Transplantation 2002; 74(6): 799–804

    Article  CAS  PubMed  Google Scholar 

  51. Trulock EP, Christie JD, Edwards LB, Boucek MM, Aurora P, Taylor DO, Dobbels F, Rahmel AO, Keck BM, Hertz MI. Registry of the International Society for Heart and Lung Transplantation: twenty-fourth official adult lung and heart-lung transplantation report—2007. J Heart Lung Transplant 2007; 26(8): 782–795

    Article  PubMed  Google Scholar 

  52. Tait BD, Süsal C, Gebel HM, Nickerson PW, Zachary AA, Claas FH, Reed EF, Bray RA, Campbell P, Chapman JR, Coates PT, Colvin RB, Cozzi E, Doxiadis II, Fuggle SV, Gill J, Glotz D, Lachmann N, Mohanakumar T, Suciu-Foca N, Sumitran-Holgersson S, Tanabe K, Taylor CJ, Tyan DB, Webster A, Zeevi A, Opelz G. Consensus guidelines on the testing and clinical management issues associated with HLA and non-HLA antibodies in transplantation. Transplantation 2013; 95(1): 19–47

    Article  CAS  PubMed  Google Scholar 

  53. Jaramillo A, Smith MA, Phelan D, Sundaresan S, Trulock EP, Lynch JP, Cooper JD, Patterson GA, Mohanakumar T. Development of ELISA-detected anti-HLA antibodies precedes the development of bronchiolitis obliterans syndrome and correlates with progressive decline in pulmonary function after lung transplantation. Transplantation 1999; 67(8): 1155–1161

    Article  CAS  PubMed  Google Scholar 

  54. Girnita AL, Duquesnoy R. Yousem SA, Iacono AT, Corcoran TE, Buzoianu M, Johnson B, Spichty KJ, Dauber JH, Burckart G, Griffith BP, McCurry KR, Zeevi A. HLA-specific antibodies are risk factors forlymphocytic bronchiolitis and chronic lung allograft dysfunction. Am J Transplant 2005; 5: 131–138

    Article  CAS  PubMed  Google Scholar 

  55. Cardarelli F, Pascual M, Tolkoff-Rubin N, Delmonico FL, Wong W, Schoenfeld DA, Zhang H, Cosimi AB, Saidman SL. Prevalence and significance of anti-HLA and donor-specific antibodies longterm after renal transplantation. Transpl Int 2005; 18(5): 532–540

    Article  PubMed  Google Scholar 

  56. Lachmann N, Terasaki PI, Schönemann C. Donor-specific HLA antibodies in chronic renal allograft rejection: a prospective trial with a four-year follow-up. Clin Transpl 2006; 2006:171–199

    Google Scholar 

  57. Otten HG, Verhaar MC, Borst HP, Hené RJ, van Zuilen AD. Pretransplant donor-specific HLA class-I and -II antibodies are associated with an increased risk for kidney graft failure. Am J Transplant 2012; 12(6): 1618–1623

    Article  CAS  PubMed  Google Scholar 

  58. Reznik SI, Jaramillo A, Zhang L, Patterson GA, Cooper JD, Mohanakumar T. Anti-HLA antibody binding to HLA class I molecules induces proliferation of airway epithelial cells: a potential mechanism for bronchiolitis obliterans syndrome. J Thorac Cardiovasc Surg 2000; 119(1): 39–45

    Article  CAS  PubMed  Google Scholar 

  59. Kim M, Townsend KR, Wood IG, Boukedes S, Guleria I, Gabardi S, El-Chemaly S, Camp PC, Chandraker AK, Milford EL, Goldberg HJ. Impact of pretransplant anti-HLA antibodies on outcomes in lung transplant candidates. Am J Respir Crit Care Med 2014; 189(10): 1234–1239

    Article  PubMed  Google Scholar 

  60. Wiebe C, Pochinco D, Blydt-Hansen TD, Ho J, Birk PE, Karpinski M, Goldberg A, Storsley LJ, Gibson IW, Rush DN, Nickerson PW. Class II HLA epitope matching—a strategy to minimize de novo donor-specific antibody development and improve outcomes. Am J Transpl 2013; 13: 3114–3122

    Article  CAS  Google Scholar 

  61. Colvin RB. Antibody-mediated renal allograft rejection: diagnosis and pathogenesis. J Am Soc Nephrol 2007; 18(4): 1046–1056

    Article  CAS  PubMed  Google Scholar 

  62. Song EY, Lee YJ, Hyun J, Kim YS, Ahn C, Ha J, Kim SJ, Park MH. Clinical relevance of pretransplant HLA class II donorspecific antibodies in renal transplantation patients with negative Tcell cytotoxicity crossmatches. Ann Lab Med 2012; 32(2): 139–144

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  63. Bieri M, Oroszlan M, Farkas A, Ligeti N, Bieri J, Mohacsi P. Anti-HLA I antibodies induce VEGF production by endothelial cells, which increases proliferation and paracellular permeability. Int J Biochem Cell Biol 2009; 41(12): 2422–2430

    Article  CAS  PubMed  Google Scholar 

  64. Lefaucheur C, Loupy A, Hill GS, Andrade J, Nochy D, Antoine C, Gautreau C, Charron D, Glotz D, Suberbielle-Boissel C. Preexisting donor-specific HLA antibodies predict outcome in kidney transplantation. J Am Soc Nephrol 2010; 21(8): 1398–1406

    Article  PubMed  PubMed Central  Google Scholar 

  65. Lefaucheur C, Antoine C, Suberbielle C, Glotz D. Mastering the risk of HLA antibodies in kidney transplantation: an algorithm based on pretransplant single-antigen flow bead techniques. Am J Transplant 2011; 11(8): 1592–1598

    Article  CAS  PubMed  Google Scholar 

  66. Safavi S, Robinson DR, Soresi S, Carby M, Smith JD. De novo donor HLA-specific antibodies predict development of bronchiolitis obliterans syndrome after lung transplantation. J Heart Lung Transplant 2014; 33(12): 1273–1281

    Article  PubMed  Google Scholar 

  67. Witt CA, Gaut JP, Yusen RD, Byers DE, Iuppa JA, Bennett Bain K, Alexander Patterson G, Mohanakumar T, Trulock EP, Hachem RR. Acute antibody-mediated rejection after lung transplantation. J Heart Lung Transplant 2013; 32(10): 1034–1040

    Article  PubMed  Google Scholar 

  68. Smith JD, Banner NR, Hamour IM, Ozawa M, Goh A, Robinson D, Terasaki PI, Rose ML. De novo donor HLA-specific antibodies after heart transplantation are an independent predictor of poor patient survival. Am J Transplant 2011; 11(2): 312–319

    Article  CAS  PubMed  Google Scholar 

  69. Roux A, Bendib Le Lan I, Holifanjaniaina S, Thomas KA, Hamid AM, Picard C, Grenet D, De Miranda S, Douvry B, Beaumont-Azuar L, Sage E, Devaquet J, Cuquemelle E, Le Guen M, Spreafico R, Suberbielle-Boissel C, Stern M, Parquin F; Foch Lung Transplantation Group. Antibody-mediated rejection in lung transplantation: clinical outcomes and donor-specific antibody characteristics. Am J Transplant 2016; 16(4): 1216–1228

    Article  CAS  PubMed  Google Scholar 

  70. Kopchaliiska D, Kukreja J, Dincheva G, Bush E, Leard L, Singer J, Brzezinski M, Hays S, Rajalingam R. IVIG infusion deplete donorspecific HLA antibodies in lung transplant recipients: a singlecenter experience. Hum Immunol 2015; 76(Suppl): 14–37

    Article  Google Scholar 

  71. Stern M, Hirsch H, Cusini A, van Delden C, Manuel O, Meylan P, Boggian K, Mueller NJ, Dickenmann M; Members of Swiss Transplant Cohort Study. Cytomegalovirus serology and replication remain associated with solid organ graft rejection and graft loss in the era of prophylactic treatment. Transplantation 2014; 98(9): 1013–1018

    Article  CAS  PubMed  Google Scholar 

  72. Baxter-Lowe L, Singer J, Hays S, Kukreja J, Golden J, Leard L. Late after lung transplantation many patients have donor-specific HLA antibodies (DSA) and high DSA levels appear to be associated with poor outcomes. Am J Transplant 2013; 13 (suppl 5) [abstract]

    Google Scholar 

  73. Zeevi A, Marrari M, Spichty K, Morrell M, Gries C, McDyer J, Pilewski J, Zaldonis D, Bhama J, Shigemura N, Yousem S, Duquesnoy R, D’Cunha J, Bermudez C. Increased frequency of class II HLA-DQ donor-specific antibodies is associated with mixed cellular and humoral rejection in lungtransplantation. J Heart Lung Transplant 2013; 32(4 4S): S76

    Article  Google Scholar 

  74. Tikkanen JM, Singer LG, Kim SJ, Li Y, Binnie M, Chaparro C, Chow CW, Martinu T, Azad S, Keshavjee S, Tinckam K. De novo DQ donor-specific antibodies are associated with chronic lung allograft dysfunction after lung transplantation. Am J Respir Crit Care Med 2016; 194(5): 596–606

    Article  CAS  PubMed  Google Scholar 

  75. Loupy A, Lefaucheur C, Vernerey D, Prugger C, Duong van Huyen JP, Mooney N, Suberbielle C, Frémeaux-Bacchi V, Méjean A, Desgrandchamps F, Anglicheau D, Nochy D, Charron D, Empana JP, Delahousse M, Legendre C, Glotz D, Hill GS, Zeevi A, Jouven X. Complement-binding anti-HLA antibodies and kidney-allograft survival. N Engl J Med 2013; 369(13): 1215–1226

    Article  CAS  PubMed  Google Scholar 

  76. Yell M, Muth BL, Kaufman DB, Djamali A, Ellis TM. C1q binding activity of de novo donor-specific HLA antibodies in renal transplant recipients with and without antibody-mediated rejection. Transplantation 2015; 99(6): 1151–1155

    Article  CAS  PubMed  Google Scholar 

  77. Sicard A, Ducreux S, Rabeyrin M, Couzi L, McGregor B, Badet L, Scoazec JY, Bachelet T, Lepreux S, Visentin J, Merville P, Fremeaux-Bacchi V, Morelon E, Taupin JL, Dubois V, Thaunat O. Detection of C3d-binding donor-specific anti-HLA antibodies at diagnosis of humoral rejection predicts renal graft loss. J Am Soc Nephrol 2015; 26(2): 457–467

    Article  CAS  PubMed  Google Scholar 

  78. Strainic MG, Liu J, Huang D, An F, Lalli PN, Muqim N, Shapiro VS, Dubyak GR, Heeger PS, Medof ME. Locally produced complement fragments C5a and C3a provide both costimulatory and survival signals to naive CD4+ T cells. Immunity 2008; 28(3): 425–435

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  79. Westall GP, Snell GI, McLean C, Kotsimbos T,Williams T, Magro C. C3d and C4d deposition early after lung transplantation. J Heart Lung Transplant 2008; 27(7): 722–728

    Article  PubMed  Google Scholar 

  80. Lepin EJ, Zhang Q, Zhang X, Jindra PT, Hong LS, Ayele P, Peralta MV, Gjertson DW, Kobashigawa JA, Wallace WD, Fishbein MC, Reed EF. Phosphorylated S6 ribosomal protein: a novel biomarker of antibody-mediated rejection in heart allografts. Am J Transplant 2006; 6(7): 1560–1571

    Article  CAS  PubMed  Google Scholar 

  81. Hirohashi T, Chase CM, Della Pelle P, Sebastian D, Alessandrini A, Madsen JC, Russell PS, Colvin RB. A novel pathway of chronic allograft rejection mediated by NK cells and alloantibody. Am J Transplant 2012; 12(2): 313–321

    Article  CAS  PubMed  Google Scholar 

  82. Zhang X, Reed EF. Effect of antibodies on endothelium. Am J Transplant 2009; 9(11): 2459–2465

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  83. Li F,Wei J, Valenzuela NM, Lai C, Zhang Q, Gjertson D, Fishbein MC, Kobashigawa JA, Deng M, Reed EF. Phosphorylated S6 kinase and S6 ribosomal protein are diagnostic markers of antibody-mediated rejection in heart allografts. J Heart Lung Transplant 2015; 34(4): 580–587

    Article  CAS  PubMed  Google Scholar 

  84. Le Bas-Bernardet S, Coupel S, Chauveau A, Soulillou JP, Charreau B. Vascular endothelial cells evade apoptosis triggered by human leukocyte antigen-DR ligation mediated by allospecific antibodies. Transplantation 2004; 78(12): 1729–1739

    Article  PubMed  Google Scholar 

  85. Lion J, Taflin C, Cross AR, Robledo-Sarmiento M, Mariotto E, Savenay A, Carmagnat M, Suberbielle C, Charron D, Haziot A, Glotz D, Mooney N. HLA class II antibody activation of endothelial cells promotes Th17 and disrupts regulatory T lymphocyte expansion. Am J Transplant 2016; 16(5): 1408–1420

    Article  CAS  PubMed  Google Scholar 

  86. Deteix C, Attuil-Audenis V, Duthey A, Patey N, McGregor B, Dubois V, Caligiuri G, Graff-Dubois S, Morelon E, Thaunat O. Intragraft Th17 infiltrate promotes lymphoid neogenesis and hastens clinical chronic rejection. J Immunol 2010; 184(9): 5344–5351

    Article  CAS  PubMed  Google Scholar 

  87. Basha HI, Ramachandran S, Tiriveedhi V, Takenaka M, Sub-ramanian V, Nath DS, Benshoff N, Patterson GA, Mohanakumar T. Critical role for IL-17A/F in the immunopathogenesis of obliterative airway disease induced by anti-MHC I antibodies. Transplantation 2013; 95(2): 293–300

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  88. Jane-wit D, Manes TD, Yi T, Qin L, Clark P, Kirkiles-Smith NC, Abrahimi P, Devalliere J, Moeckel G, Kulkarni S, Tellides G, Pober JS. Alloantibody and complement promote T cell-mediated cardiac allograft vasculopathy through noncanonical nuclear factor-kB signaling in endothelial cells. Circulation 2013; 128(23): 2504–2516

    Article  CAS  PubMed  Google Scholar 

  89. Mezzetti M, Soloperto M, Fasoli A, Mattoli S. Human bronchial epithelial cells modulate CD3 and mitogen-induced DNA synthesis in T cells but function poorly as antigen-presenting cells compared to pulmonary macrophages. J Allergy Clin Immunol 1991; 87(5): 930–938

    Article  CAS  PubMed  Google Scholar 

  90. Cunningham AC, Zhang JG, Moy JV, Ali S, Kirby JA. A comparison of the antigen-presenting capabilities of class II MHCexpressing human lung epithelial and endothelial cells. Immunology 1997; 91(3): 458–463

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  91. Hidalgo LG, Sellares J, Sis B, Mengel M, Chang J, Halloran PF. Interpreting NK cell transcripts versus T cell transcripts in renal transplant biopsies. Am J Transplant 2012; 12(5): 1180–1191

    Article  CAS  PubMed  Google Scholar 

  92. Parkes MD, Halloran PF, Hidalgo LG. Evidence for CD16amediated NK cell stimulation in antibody-mediated kidney transplant rejection. Transplantation 2017; 101(4): e102–e111

    Article  CAS  PubMed  Google Scholar 

  93. Saini D, Angaswamy N, Tiriveedhi V, Fukami N, Ramachandran S, Hachem R, Trulock E, Meyers B, Patterson A, Mohanakumar T. Synergistic effect of antibodies to human leukocyte antigens and defensins in pathogenesis of bronchiolitis obliterans syndrome after human lung transplantation. J Heart Lung Transplant 2010; 29(12): 1330–1336

    Article  PubMed  PubMed Central  Google Scholar 

  94. Fukami N, Ramachandran S, Saini D, Walter M, Chapman W, Patterson GA, Mohanakumar T. Antibodies to MHC class I induce autoimmunity: role in the pathogenesis of chronic rejection. J Immunol 2009; 182(1): 309–318

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  95. Jaramillo A, Smith CR, Maruyama T, Zhang L, Patterson GA, Mohanakumar T. Anti-HLA class I antibody binding to airway epithelial cells induces production of fibrogenic growth factors and apoptotic cell death: a possible mechanism for bronchiolitis obliterans syndrome. Hum Immunol 2003; 64(5): 521–529

    Article  CAS  PubMed  Google Scholar 

  96. Hill GS, Nochy D, Bruneval P, Duong van Huyen JP, Glotz D, Suberbielle C, Zuber J, Anglicheau D, Empana JP, Legendre C, Loupy A. Donor-specific antibodies accelerate arteriosclerosis after kidney transplantation. J Am Soc Nephrol 2011; 22(5): 975–983

    Article  PubMed  PubMed Central  Google Scholar 

  97. Maruyama T, Jaramillo A, Narayanan K, Higuchi T, Mohanakumar T. Induction of obliterative airway disease by anti-HLA class I antibodies. Am J Transplant 2005; 5(9): 2126–2134

    Article  CAS  PubMed  Google Scholar 

  98. Yamada Y, Sekine Y, Yoshida S, Yasufuku K, Petrache I, Benson HL, Brand DD, Yoshino I, Wilkes DS. Type V collagen-induced oral tolerance plus low-dose cyclosporine prevents rejection of MHC class I and II incompatible lung allografts. J Immunol 2009; 183(1): 237–245

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  99. Xu Z, Nayak DK, Benshoff N, Hachem R, Gelman AE, Mohanakumar T. De novo-developed antibodies to donor MHC antigens lead to dysregulation of microRNAs and induction of MHC class II. J Immunol 2015; 194(12): 6133–6143

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  100. Nayak DK, Zhou F, Xu M, Huang J, Tsuji M, Yu J, Hachem R, Gelman AE, Bremner RM, Smith MA, Mohanakumar T. Zbtb7a induction in alveolar macrophages is implicated in anti-HLAmediated lung allograft rejection. Sci Transl Med 2017; 9(398): eaal1243

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  101. Otani S, Davis AK, Cantwell L, Ivulich S, Pham A, Paraskeva MA, Snell GI, Westall GP. Evolving experience of treating antibodymediated rejection following lung transplantation. Transpl Immunol 2014; 31(2): 75–80

    Article  CAS  PubMed  Google Scholar 

  102. Rodey GE, Fuller TC. Public epitopes and the antigenic structure of the HLA molecules. Crit Rev Immunol 1987; 7(3): 229–267

    CAS  PubMed  Google Scholar 

  103. Ayala García MA, González Yebra B, López Flores AL, Guaní Guerra E. The major histocompatibility complex in transplantation. J Transplant 2012; 2012: 842141

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  104. Opelz G, Mytilineos J, Scherer S, Dunckley H, Trejaut J, Chapman J, Middleton D, Savage D, Fischer O, Bignon JD, Bensa JC, Albert E, Noreen H; The Collaborative Transplant Study. Survival of DNA HLA-DR typed and matched cadaver kidney transplants. Lancet 1991; 338(8765): 461–463

    Article  CAS  PubMed  Google Scholar 

  105. Takemoto SK, Terasaki PI, Gjertson DW, Cecka JM. Twelve years’ experience with national sharing of HLA-matched cadaveric kidneys for transplantation. N Engl J Med 2000; 343(15): 1078–1084

    Article  CAS  PubMed  Google Scholar 

  106. Rubinstein P. HLA matching for bone marrow transplantation— how much is enough? N Engl J Med 2001; 345(25): 1842–1844

    Article  CAS  PubMed  Google Scholar 

  107. Kawase T, Matsuo K, Kashiwase K, Inoko H, Saji H, Ogawa S, Kato S, Sasazuki T, Kodera Y, Morishima Y; Japan Marrow Donor Program. HLA mismatch combinations associated with decreased risk of relapse: implications for the molecular mechanism. Blood 2009; 113: 2851–2858

    Article  CAS  PubMed  Google Scholar 

  108. Chin N, Paraskeva M, Paul E, Cantwell L, Levvey B, Williams T, Snell G, Westall G. Comparative analysis of how immune sensitization is defined prior to lung transplantation. Hum Immunol 2015; 76(10): 711–716

    Article  CAS  PubMed  Google Scholar 

  109. Burton CM, Iversen M, Milman N, Zemtsovski M, Carlsen J, Steinbrüchel D, Mortensen J, Andersen CB. Outcome of lung transplanted patients with primary graft dysfunction. Eur J Cardiothorac Surg 2007; 31(1): 75–82

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. HLA et Medecine, “Jean Dausset” Laboratory Network, Hôpital Saint-Louis, Paris, France

    Liya Ju & Dominique Charron

  2. Laboratoire Histocompatibilité, Hôpital Saint-Louis, Paris, France

    Caroline Suberbielle & Dominique Charron

  3. INSERM U1160, Hôpital Saint-Louis, Université Paris Diderot, Sorbonne Paris Cité, France

    Xiaofan Li & Nuala Mooney

  4. Labex Transplantex, Strasbourg, France

    Nuala Mooney & Dominique Charron

  5. Shanghai Jiao Tong University School of Medicine, Shanghai, 200025, China

    Dominique Charron

Authors
  1. Liya Ju
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Caroline Suberbielle
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Xiaofan Li
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Nuala Mooney
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Dominique Charron
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Liya Ju.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Ju, L., Suberbielle, C., Li, X. et al. HLA and lung transplantation. Front. Med. 13, 298–313 (2019). https://doi.org/10.1007/s11684-018-0636-x

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11684-018-0636-x

Keywords

Search

Navigation